Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis - Wikidata - wikimedia - TriplyDB

Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis

Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis

http://www.wikidata.org/entity/Q33693084

about

Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections Profile of oritavancin and its potential in the treatment of acute bacterial skin structure infections Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis.Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis Oritavancin for acute bacterial skin and skin structure infections.Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review.Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin.Oritavancin Pharmacokinetics and Bone Penetration in Rabbits.

P2860

Q26772897-3D1198BA-D540-4928-AEF1-5978CD9C9025 Q26799701-6DF75366-0950-4BC2-A10C-81BFDD6C021F Q33594048-BDA8A8E2-3987-44D9-B519-E13207227C3D Q33975885-373714A1-FF05-4643-ACBC-A30B17066B27 Q35013994-FD2AA6E1-5768-43D9-ACAD-A3FE52D5626E Q36086423-73F8355C-7F36-4EAD-A745-B77EC0EE27D4 Q38364691-C78296BC-0CF4-4D3A-B678-C8DF87C5183D Q39477892-FCD2276B-0ACB-490C-B90B-BDC4431DF696 Q41073732-427E5B50-E5AA-45CA-A32D-E4ED501B415E

P2860

Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis

http://www.wikidata.org/entity/Q33693084

description

1998 nî lūn-bûn

@nan

1998 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

1998 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

1998年の論文

@ja

1998年論文

@yue

1998年論文

@zh-hant

1998年論文

@zh-hk

1998年論文

@zh-mo

1998年論文

@zh-tw

1998年论文

@wuu

name

Efficacy of LY333328 against e ...... hylococcus aureus endocarditis

@ast

Efficacy of LY333328 against e ...... hylococcus aureus endocarditis

@en

type

label

Efficacy of LY333328 against e ...... hylococcus aureus endocarditis

@ast

Efficacy of LY333328 against e ...... hylococcus aureus endocarditis

@en

prefLabel

Efficacy of LY333328 against e ...... hylococcus aureus endocarditis

@ast

Efficacy of LY333328 against e ...... hylococcus aureus endocarditis

@en

P1433

Q33693084-22BDDCE7-0A70-43B6-8A62-8B2F58620B63

P1476

Q33693084-71F209F8-721F-4E6F-8BEA-A49BE162B0E0

P2093

Q33693084-093E52C2-D106-4C44-BFCD-AD0A205820B0

Q33693084-839D1EC4-D7B9-4D5B-A766-B96B540E0148

Q33693084-991C50DF-A529-437C-A354-926F8A0DFFF7

Q33693084-C5E3A590-2B0A-44E1-BBF1-887D67CED33A

Q33693084-D660F5AB-E3E6-4D7E-85BC-758ACB00E1A1

Q33693084-DAA238A4-6AE0-47EE-A416-AAFF7DE15799

P2860

Q33693084-317A8360-F209-48D9-90F2-964BB210473A

Q33693084-32D30E12-50CE-4CA2-9C86-D827D1723F44

Q33693084-39A80B2D-FDCB-4FC7-898E-4C8381541808

Q33693084-45A1CF57-D693-4555-B269-97B56AC08ECF

Q33693084-4E372855-AEC7-4F67-820F-27F7A0118FBE

Q33693084-72355AB6-6464-4776-9522-03E0241FD131

Q33693084-8E42A934-E04F-43C7-97F8-9634CFE00C2D

Q33693084-9C1AF4A3-F62D-4D74-A49D-756820CF19FC

Q33693084-A2F7119C-CE8B-4D52-AD2C-4DD846649F30

Q33693084-C5F6B911-70D5-40EF-9757-B43A6233A63E

P304

Q33693084-23B7C50D-4CB8-46F2-ADA4-D3FC9941B1FC

P31

Q33693084-B8C11829-67EC-48B3-AF30-DE606B535CF0

P407

Q33693084-43F6FA33-BE35-4A67-B358-346FB2A5EF5F

P433

Q33693084-F0B60594-820E-4792-B3CF-D9B74C449752

P478

Q33693084-15A67979-C2A0-4130-98BF-B84FFEA9E88B

P577

Q33693084-79AC6ED4-4586-4C4D-A159-83E191E4DBCA

P698

Q33693084-3D3B13FA-337F-4ED0-9CEA-35F1D970B712

P921

Q33693084-73FA267A-430B-4084-AC5E-C46560652318

P932

Q33693084-8A65D2B1-4FE1-4237-AC6D-B87711DC30D7

P1433

Antimicrobial Agents and Chemotherapy

P1476

Efficacy of LY333328 against e ...... hylococcus aureus endocarditis

@en

P2093

G W Kaatz

http://www.w3.org/2001/XMLSchema#string

H H Houlihan

http://www.w3.org/2001/XMLSchema#string

J R Aeschlimann

http://www.w3.org/2001/XMLSchema#string

M J Rybak

http://www.w3.org/2001/XMLSchema#string

R C Mercier

http://www.w3.org/2001/XMLSchema#string

S M Seo

http://www.w3.org/2001/XMLSchema#string

P2860

Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci

In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci.

In vitro activity and spectrum of LY333328, a novel glycopeptide derivative.

Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium

Efficacy of ofloxacin in experimental Staphylococcus aureus endocarditis

Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group.

Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis.

Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin.

Time-kill curves for a semisynthetic glycopeptide, LY333328, against vancomycin-susceptible and vancomycin-resistant Enterococcus faecium strains.

Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus.

P304

981-983

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P577

1998-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

9559828

http://www.w3.org/2001/XMLSchema#string

P921

methicillin-resistant Staphylococcus aureus

P932

105587

http://www.w3.org/2001/XMLSchema#string